Peloton Therapeutics PLTX 深 滬
等待開盤 09-06 09:30:00 美东时间
0.00
0.000
NaN.00%
華盛通- 最 高--
- 今 開--
- 成交量 0股
- 最 低 --
- 昨 收 0.00
- 總市值 0
- 52周最高 0.00
- 市盈率 靜 --
- 換手率 NaN.00%
- 52周最低 0.00
- 委 比 0.00%
- 總股本 0
- 歷史最高 0.00
- 量 比 0
- 振 幅 NaN.00%
- 歷史最低 0.00
- 每 手 1
- 風險率
個股概要
財務分析
公司資料
相關新聞
分紅派息
- 分時圖
- 日k
- 周k
- 月k
相關新聞
更多Lesaka to Host Webcast and Conference Call to Review Fourth Quarter and Year-End 2025 Results on September 11, 2025
Lesaka Technologies plans to release its fourth quarter and year-end 2025 results after the U.S. market close on September 10, 2025. A presentation webcast and conference call will be held on September 11, 2025, at 8:00am EDT (2:00pm SAST), followed by a Q&A session. The webcast can be accessed at https://www.corpcam.com/Lesaka11092025, and participants can submit questions during the live session. For the conference call, registration is require...
08-26 20:05
Plus Therapeutics Regains Compliance with Applicable Nasdaq Listing Criteria
Plus Therapeutics, Inc. (Nasdaq: PSTV), a clinical-stage pharmaceutical company, has confirmed compliance with Nasdaq Listing Rule 5550(b), meeting both the MVLS Standard ($35 million market value) and Equity Standard ($2.5 million stockholders' equity). As a result, the Company no longer needs to perform a reverse stock split to meet the Bid Price Rule. Nasdaq has extended the compliance grace period for the $1.00 bid price rule through November...
08-26 11:30
Lisata Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update
Lisata Therapeutics reported a business update and Q2 2025 financial results. The company has a cash runway extending into Q4 2026 with no debt, funding current clinical programs through their next data milestones. Clinical trials include ASCEND, BOLSTER, and CENDIFOX, showing positive preliminary data for certepetide in treating solid tumors. Q2 revenue was $70K, down from Q2 2024 due to no revenue in the prior year. Operating expenses decreased...
08-07 20:05
Lisata Therapeutics to Report Second Quarter 2025 Financial Results and Provide a Business Update on Thursday, August 7, 2025
Lisata Therapeutics announced it will report its second-quarter 2025 financial results on August 7, 2025, followed by a conference call at 4:30 p.m. ET. Interested parties must register via the provided link to receive dial-in details. The call will also be webcast on the company's website and available for replay for 12 months. Lisata focuses on developing therapies for advanced solid tumors, with its candidate certepetide aiming to improve drug...
07-31 12:00
Plus Therapeutics Announces FDA Clearance of its Investigational New Drug Application using REYOBIQTM for the Treatment of Childhood Brain Cancer
Plus Therapeutics announced FDA clearance for its IND application for REYOBIQ™, a targeted radiotherapeutic, in a Phase 1/2a clinical trial for pediatric patients with recurrent, refractory, or progressive high-grade glioma and ependymoma. The trial, named ReSPECT-PBC, is funded by a $3.0M grant from the U.S. Department of Defense. The study aims to determine the maximum tolerated dose and assess safety, tolerability, and efficacy. REYOBIQ™ lever...
06-25 11:30
礼来替尔泊肽、阿斯利康和安进TSLP 单抗国内报上市，默沙东抗肿瘤新药国内获批
礼来的替尔泊肽在国内报上市 今日，CDE 官网显示，替尔泊肽新适应症在国内报上市。这是礼来在中国递交的第 4 项上市申请。 替尔泊肽注射液（Tirze...
2024-11-22 17:17
被忽视的金子：老牌药企业绩大反转
贝达药业“吃老本”已经被诟病了数年，数年的隐忍和努力，如今终于有摆脱标签的机会。 7月23日晚，贝达药业发布2024H1业绩预告：2024年半年度归属于上市公司...
2024-07-26 10:14
开盘：美股周四高开 市场情绪谨慎
查看最新行情 北京时间29日晚，美股周四高开。2022年美股交易进入收官阶段，投资者情绪谨慎，股市交投清淡。美国上周首次申请失业救济人数为2...
2022-12-29 22:30
美股异动丨三大指数低开低走，流媒体平台Roku大跌15%
多家公司遭遇“业绩杀”，网红健身平台Peloton跌12.98%，第二季度营收指引不及预期；高通跌8.44%，Moderna一度跌超8%；部分公司业绩符合预期，盘中逆势走强，互联网公司Starry Group涨超20%>>
2022-11-03 22:02
美股前瞻 | 美联储会议纪要公布在即！美国9月PPI同比增速放缓
美国9月PPI数据公布后，三大期指涨幅收窄；美股将触底？美银数据显示：美股上周资金流入接近纪录新高；芒格第三季按兵不动，未减持阿里巴巴>>
2022-10-12 20:43
